– CANADA, Vancouver – AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced the appointment of Dr. Andrew Lo (Ph.D.) to its Board as an independent director, effective immediately.
The company also announced the resignation of Dr. John Hamer effective immediately.
He will join the Audit and Compensation Committees.
“Andrew is a distinguished economist, professor, author, and strategist whose work in connecting financial structures, business models, and biomedical innovation has resulted in exciting new approaches that help bring treatments to patients faster. We welcome him to our board and look forward to working with him as we continue to build a large and diversified portfolio of positions in the next generation of antibody therapies, driving long-term value for patients, partners, and our shareholders,” commented CEO and Chairman, Dr. Carl Hansen. CEO.
About Dr. Andrew W. Lo
Dr. Lo has developed new financial engineering tools and business models for drug and device development and healthcare delivery, statistical methods for incorporating patient preferences into the drug approval process, and machine-learning for predicting clinical trial outcomes.
Dr. Lo is a co-founder and director of BridgeBio Pharma, a director of Atomwise and Roivant Sciences, a co-founder and chairman of QLS Advisors, and a member of the advisory boards of NCATS and the American Cancer Society’s BrightEdge Impact Fund. He is currently the Charles E. and Susan T. Harris Professor at the MIT Sloan School of Management, director of MIT’s Laboratory for Financial Engineering, and principal investigator at MIT’s Computer Science and Artificial Intelligence Laboratory. Dr. Lo was named one of TIME’s “100 most influential people in the world.”
“I’m delighted and honored to be joining AbCellera’s board. Their unique partnership-based business model draws on key financial insights to build value,” said Dr. Lo. “I look forward to working with them to help them realize the enormous impact their approach can have on the industry and, ultimately, on patients around the world.”
About AbCellera Biologics Inc.
AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce cost, and tackle the toughest problems in drug development.
For more information: https://www.abcellera.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.